Flerie publishes annual report 2025

Regulatory

Flerie AB (publ) has published its 2025 annual report on www.flerie.com.

In the annual report, CEO Ted Fjällman highlights how the year was defined by active portfolio management, strategic mergers and divestments to sharpen Flerie’s core business, as well as significant clinical progress across several portfolio companies.

“We are proud of our contribution and happy about the opportunity to offer both institutional investors and private individuals the opportunity to benefit from our expertise in the life science area. An investment in Flerie enables and optimises exposure to a sector that has historically been shown to both generate high returns and contribute to longer and healthier lives. I believe the biotech sector will soon regain momentum with higher valuations, even for early-stage assets.” writes Ted Fjällman, CEO.

Read more in our annual report 2025 on www.flerie.com.

For more information:
Ted Fjällman, CEO
Email: ir@flerie.com

Flerie in brief
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com

This information is information that Flerie AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-03-05 08:00 CET.

Attachments
Annual report 2025

Documents